Orphan Synergy Europe - Pharma Aktie [WKN DE: A14QXP / ISIN: FR0012127173]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Orphan Synergy Europe - Pharma SA

11.12.24		OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi® (GlobeNewswire)
02.12.24		OSE Immunotherapeutics Strengthens Leadership and Executive Committee (GlobeNewswire)
04.11.24		OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis (GlobeNewswire)
17.10.24		OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index (GlobeNewswire)
26.09.24		OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update (GlobeNewswire)
10.09.24		OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer (GlobeNewswire)
24.07.24		OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis (GlobeNewswire)
03.07.24		Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371 (GlobeNewswire)
01.07.24		OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’ (GlobeNewswire)
24.06.24		OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies (GlobeNewswire)
20.06.24		OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco (June 18 – 21) (GlobeNewswire)
19.06.24		OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s Growth (GlobeNewswire)
12.06.24		OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin Besse (GlobeNewswire)
05.06.24		OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant (GlobeNewswire)
30.05.24		OSE Immunotherapeutics Provides Business and Corporate Update (GlobeNewswire)
22.05.24		OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases (GlobeNewswire)
16.04.24		OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective (GlobeNewswire)
10.04.24		OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer (GlobeNewswire)
02.04.24		OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology (GlobeNewswire)
27.03.24		OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update (GlobeNewswire)
27.03.24		OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update (Businesswire)
19.01.24		OSE Immunotherapeutics Highlights Clinical Portfolio Advancements and Provides 2024 Outlook (Businesswire)
16.10.23		OSE Immunotherapeutics Presents First Positive Clinical Results With its anti-PD1 OSE-279 in Advanced Solid Tumors (Businesswire)
27.09.23		OSE Immunotherapeutics Announces H1 2023 Results and Provides Corporate Update (Businesswire)
11.09.23		OSE Immunotherapeutics Announces: Positive Phase 3 Data from its Cancer Vaccine in Lung Cancer Patients with Resistance to Previous Immunotherapy Published in Annals of Oncology (Businesswire)
06.07.23		OSE Immunotherapeutics Announces for Lusvertikimab, its Anti-IL-7 Receptor Antagonist: (Businesswire)
04.07.23		OSE Immunotherapeutics Announces New US Patent Granted for the Use of Tedopi® in Cancer Patients after Failure with PD-1/PD-L1 Immune Checkpoint Inhibitor Treatment (Businesswire)
20.06.23		OSE Immunotherapeutics Receives €1.5 M in Funding from Bpifrance for the Development of a Companion Diagnostic for the Cancer Vaccine Tedopi® in Non-Small Cell Lung Cancer (Businesswire)
15.06.23		OSE Immunotherapeutics Presents Update on BiCKI®IL-7, CLEC-1 and OSE-230 Preclinical Programs in Immuno-Oncology and Immuno-Inflammation At International Conferences (Businesswire)
26.05.23		OSE Immunotherapeutics (OSE): Re-initiation Milestones anticipated throughout FY23 (EQS Group)
27.04.23		OSE Immunotherapeutics Reports Full Year 2022 Financial Results and Provides Business Strategy Update (Businesswire)
20.04.23		OSE Immunotherapeutics Presents Additional Preclinical Updates on CLEC-1, a Novel Myeloid Immune Checkpoint in Immuno-Oncology (Businesswire)
18.04.23		OSE Immunotherapeutics Presents Clinical and Preclinical Data from its Immuno-Oncology Portfolio (Businesswire)
15.02.23		OSE Immunotherapeutics Provides Regulatory Update on Tedopi®, a Cancer Vaccine at a Late-Stage Clinical Development in Lung Cancer After Failure to Immunotherapies (Businesswire)
27.05.21		OSE Immunotherapeutics and the FoRT Foundation Announce Initiation of a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo® (nivolumab) in Non-Small Cell Lung Cancer (Businesswire)
16.11.20		OSE IMMUNOTHERAPEUTICS: Trading suspension (Businesswire)
06.12.18		Edison initiates coverage on OSE Immunotherapeutics (OSE) (EQS Group)
28.02.18		OSE Immunotherapeutics Presenting at the Annual International Conference BIO-EUROPE SPRING® (Businesswire)
04.01.18		OSE Immunotherapeutics to Present at Biotech Showcase™ 2018 Conference (Businesswire)
03.01.18		OSE Immunotherapeutics Announces Appointment of Gérard Tardy as Chairman of Company’s Board of Directors (Businesswire)
19.12.17		OSE Immunotherapeutics Presents New Data Analysis Supporting Continued Development of OSE-127 in Inflammatory Bowel Diseases (Businesswire)
14.12.17		OSE Immunotherapeutics Receives a Grant from French Government Program "Fonds Unique Interministériel” to Explore New Cytotoxic Antibodies (Businesswire)
07.12.17		OSE Immunotherapeutics to Resume Accrual in Phase 3 Clinical Trial of Tedopi® in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment (Businesswire)
26.10.17		OSE Immunotherapeutics Presenting at the 23rd Annual International Partnering Conference BIO-EUROPE® (Businesswire)
19.10.17		OSE Immunotherapeutics Publishes New Data on FR104, CD28-Antagonist Immunotherapy (Businesswire)
02.10.17		OSE Immunotherapeutics Presents New Data Strengthening the Rationale of Myeloid Checkpoint Inhibitor OSE-172 as an Immune Cancer Treatment (Businesswire)
28.09.17		OSE Immunotherapeutics Signs a License Option Agreement with Inserm to Develop a New Cancer Immunotherapy Targeting Myeloid Cells (Businesswire)
26.09.17		Selexis SA and OSE Immunotherapeutics Expand Strategic Alliance to Further Advance OSE’s OSE-172 and OSE-703 Cancer Immunotherapy Programs (Businesswire)
26.09.17		Selexis SA and OSE Immunotherapeutics Expand Strategic Alliance to Further Advance OSE’s OSE-172 and OSE-703 Cancer Immunotherapy Programs (Businesswire)
07.09.17		OSE Immunotherapeutics Reports on First-Half 2017 Financial Results and Provides Update on Clinical Advances of Its Product Portfolio (Businesswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Bitcoin als Chance: MicroStrategy-Chef fordert Microsoft zu mutigem Schritt auf

Bundesheer wirbt nach KTM-Insolvenz um Mitarbeiter - Pierer Mobility-Aktie im Plus

voestalpine-Aktie gewinnt: Wiener Privatbank senkt Kursziel

Delivery-Hero-Aktie tiefrot: Delivery-Hero-Tochter Talabat nach deutlichem Kursplus bei Börsenstart unter Ausgabepreis

Ripple fällt auf 2 US-Dollar zurück – Was passiert jetzt?

TeamViewer-Aktie in Rot: TeamViewer mit größtem Zukauf - Übernahme von 1E

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	12.12.2024 16:09
Kaufwert:	EUR
	Hinzufügen Speichern